Over the years, extensive R&D efforts have established the basis for a wide range of microbiome-based therapeutic and diagnostic products, which may cause a paradigm shift in the way healthcare is delivered in the foreseen future

A steadily increasing demand for participants in clinical research studies, coupled to the complexities associated with patient enrolment, have prompted drug / therapy developers to outsource this process to specialty service providers

Liquid biopsies have emerged as a versatile diagnostic solution, especially for cases when conventional (invasive) diagnostic tests are inconclusive or when the clinical condition is related to an organ that is not amenable to biopsy access

Drug repurposing enables drug developers to optimize on past efforts and expenditure, thereby, offering a viable life cycle management strategy for marketed products and opportunities to re-evaluate failed / shelved drug development programs

Driven by the growing complexity of modern pharmacological interventions, industry stakeholders have developed container-closures systems using more versatile materials; in this context, elastomers have demonstrated significant potential

Recent advances in the manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing

Owing to the complexities associated with the production of biologics, biopharmaceutical developers are likely to continue relying on contract service providers for various aspects of their respective product development programs

Given the success of approved CAR-T cell therapies, such as KYMRIAH®, YESCARTA®, TECARTUS® and BREYANZI®, this upcoming class of biologics are anticipated to carve out a significant share of the multi-billion dollar cancer immunotherapy market

Driven by the potential to treat the root cause of diseases, including rare clinical conditions and those that were previously deemed incurable, the gene therapies pipeline is growing.

Over the years, extensive R&D efforts have established the basis for a wide range of microbiome-based therapeutic and diagnostic products, which may cause a paradigm shift in the way healthcare is delivered in the foreseen future